Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report

The Pfizer-BioNTech COVID-19 vaccine has been authorized by the U.S. Food and Drug Administration as it demonstrated 95% effectiveness against the SARS-CoV-2 virus. Although the initial vaccine trials showed a favorable side effect profile, there have been concerns regarding activation of aberrant i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemoine, Chantal, Padilla, Cristina, Krampe, Noah, Doerfler, Sean, Morgenlander, Adam, Thiel, Brent, Aggarwal, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Case Based Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924566/
https://www.ncbi.nlm.nih.gov/pubmed/35294664
http://dx.doi.org/10.1007/s10067-022-06126-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924566/
https://www.ncbi.nlm.nih.gov/pubmed/35294664
http://dx.doi.org/10.1007/s10067-022-06126-x

Ejemplares similares